THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 83 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2015. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $1,979 | -99.9% | 176,426 | +15.9% | 0.00% | +50.0% |
Q3 2022 | $1,543,000 | +250.7% | 152,177 | +795.0% | 0.00% | – |
Q4 2019 | $440,000 | -55.0% | 17,003 | -57.8% | 0.00% | -100.0% |
Q2 2018 | $977,000 | 0.0% | 40,300 | 0.0% | 0.00% | 0.0% |
Q1 2018 | $977,000 | +448.9% | 40,300 | +270.4% | 0.00% | – |
Q4 2015 | $178,000 | -94.8% | 10,880 | -95.9% | 0.00% | -100.0% |
Q2 2015 | $3,435,000 | +1535.7% | 263,816 | +1772.9% | 0.01% | +700.0% |
Q4 2014 | $210,000 | – | 14,086 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
King Wealth Management Group | 22,500 | $583,000 | 0.15% |
Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |